
As overdose deaths fall, Trump administration proposes cuts to lifesaving Narcan program
The Trump administration has proposed cutting a $56 million grant that teaches first responders how to use the lifesaving overdose reversal drug naloxone, which experts say could reverse progress the United States has made in lowering opioid overdose deaths.
A recent dip in overdose deaths has been credited in part to wider naloxone access. The medication was made available for over-the-counter purchase in 2023 and is standard for first responders to carry. It's even popped up in some classrooms.
Naloxone, also sold under the brand name Narcan, is available in injectable and nasal spray form. It is an opioid antagonist that attaches to receptors in the brain, reversing and blocking the effects of other opioids, including fentanyl.
The grant money can be used by state and local organizations for training people on how to use naloxone, as well as administering and distributing the medication. Grantees are expected to establish protocols to refer patients to treatment or support services and provide other safety information about illicit drugs and overdoses. The grant is administered by the Substance Abuse and Mental Health Services Administration.
"While some skeptics may think that naloxone - and harm reduction more generally - enable people, there is decades of research that show giving people the information and tools they need helps keep people safe," medical anthropologist Jennifer Syvertsen said in an emailed statement. "Naloxone simply enables people to breathe."
Wider cuts could "dismantle essential services"
The proposed cut comes as the Trump administration proposes cutting $33.3 billion from the Health and Human Services budget in 2026, according to the Associated Press. The cuts would eliminate SAMHSA, the AP reported in March.
Health Secretary Robert F. Kennedy Jr., who referenced his history of heroin addiction during his confirmation hearings, has proposed that the administration be absorbed into a new office. HHS has also faced mass layoffs.
These combined cuts could "dismantle essential services," Hanna Sharif-Kazemi, the federal policy manager for the Drug Policy Alliance, told CBS News. The DPA is a non-profit agency based in New York City that seeks to reduce overdose deaths with harm reduction and evidence-based methodology.
"We believe it's going to exacerbate the overdose crisis at a time when nearly 90,000 people died from overdoses last year," Sharif-Kazemi said.
The loss of federal funding, Sharif-Kazemi said, can exacerbate the budget issues that state and local agencies already face.
"Without federal funding, states may be forced to reduce essential services in other sectors, like health care, education and public safety, or they would fail to compensate for the loss in overdose prevention funding, which would put more lives at risk," Sharif-Kazemi said. "Those cuts to overdose prevention programs are going to undermine proven strategies that we know save lives."
How can the federal government support overdose prevention efforts?
During his second term, Mr. Trump has focused on fentanyl entering the United States. He has enacted tariffs on China, Canada and Mexico with the goal of making the countries fight fentanyl trafficking. Little fentanyl enters the U.S. over the northern border. Precursor chemicals, or the ingredients for fentanyl and other illicit drugs, are largely manufactured in China and shipped overseas, usually to Mexico. The fentanyl is then produced, typically in Mexico, and brought to the United States for distribution.
Sharif-Kazemi said the best way to build on the progress made in reducing overdose deaths is to continue and even expand federal funding for overdose prevention efforts. That could include expanded access to naloxone, she said, as well as better access to medication-assisted treatment, which Trump has previously pushed for, and the expansion of rehabilitation facilities. It could also include more funding for harm reduction strategies, like testing strips that allow people to check if drugs are contaminated with fentanyl.
Recent years have also seen a push for overdose prevention centers, where people who use drugs can do so under the supervision of trained medical professionals. Those medical professionals can then monitor the drug users, and administer naloxone or other medications if necessary. OnPoint NYC operates two such sites in New York City. The organization said in January that its staff have reversed over 1,700 opioid overdoses since November 2021.
"We know the 90,000 people that we lost to overdose last year were denied the care and support they needed," Sharif-Kazemi said. "These are all tools that we know actually can save people's lives. Ultimately, if the Trump administration was really worried about making sure that people entered recovery, we need to make sure they stay alive and are able to actually enter recovery."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
14-Year-Old Boy Dies from Rare Bacterial Infection Just Days After Showing Signs of Symptoms: ‘Brought Joy Everywhere'
A 14-year-old boy in South Carolina died within days of becoming ill with a rare bacterial infection William 'Will' Hand died on June 8 from meningococcal septicemia after the infection got into his bloodstream A doctor said the illness spreads through saliva and respiratory secretions and through sharing everyday items like beveragesA 14-year-old boy in South Carolina died of a rare infection within days of showing symptoms. William 'Will' Hand of Greenville died on Sunday, June 8, according to his online obituary and local news outlet Fox Carolina. His mother, Megan, told the outlet that Will had meningococcal septicemia, also known as meningococcemia, and that the infection got into his bloodstream. Dr. Anna-Kathryn Burch, an infectious disease specialist at Prisma Health Children's Hospital, where Will was treated, told Fox Carolina that infections of this nature happen 'so quickly,' adding, 'sometimes it is very hard to save the person who is infected with the bacteria.' Dr. Burch told the outlet that the illness spreads through saliva and respiratory secretions and through sharing everyday items like beverages. Symptoms include high fever, severe headache, sensitivity to light, nausea and vomiting, per the Cleveland Clinic. It can also cause a rash that does not fade when pressed. 'We call it a petechial rash because it looks like broken blood vessels underneath the skin,' Dr. Burch said of the rash while speaking to Fox Carolina. 'It's not a typical rash that you would get with, let's say, a viral infection. If you put your finger on it and press down really hard, the rash will stay there." The Centers for Disease Control states that meningococcal disease is 'uncommon,' though they note that early intervention with antibiotics is critical for treatment. Vaccines are the 'best protection' against the infection, per the CDC. Will is described by loved ones as having 'a joyful spirit, quick smile and magnetic energy,' per his online obituary. "His loss leaves a void that can never be filled," they added. 'Will was a highlight of many people's day — equal parts athlete, comedian, music lover, and loyal friend,' the obituary states, adding, "His teammates, coaches, and friends knew him as the life of party.' The teen was also known for 'turning everyday moments into unforgettable memories. Whether it was walking to CVS ... with his friends, or re-enacting WWE wrestling, he brought joy everywhere he went,' the obituary continued. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Will had just completed 8th grade at Hughes Academy in Greenville. He is survived by his parents, William and Megan, as well as two sisters and a brother, per the obituary. A celebration of Will's life was held at Westminster Presbyterian Church in Greenville on Friday, June 13. In lieu of flowers, Will's parents asked that donations be sent to Prisma Health Children's Hospital, 'where the critical care team fought tenaciously to keep our son alive.' Read the original article on People

Associated Press
an hour ago
- Associated Press
Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediates profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapies Data further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer pain These data support the Company's continuing efforts to progress with IND-enabling studies of ADB-102 gene therapy for the treatment of osteoarthritis (OA) chronic knee pain. DELRAY BEACH, FL / ACCESS Newswire / June 15, 2025 / Adolore BioTherapeutics ('Adolore' or the 'Company'), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, 'Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1,' in the peer-reviewed journal, Molecular Therapy. Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of the NIH, NINDS, HEAL Award supporting ADB-102 development for the treatment of chronic knee pain due to OA, and Founder & Executive Chairman of Adolore BioTherapeutics, published biosafety and efficacy data from preclinical studies of Adolore's gene therapy expressing a human carbonic anhydrase-8 variant peptide (CA8*). In model systems, replication-defective, disease-free, herpes simplex virus (rdHSV) gene therapy expressing an analgesic carbonic anhydrase-8 (CA8*) peptide variant corrects somatosensory hyperexcitability by activating Kv7 voltage-gated potassium channels, produces profound, long-lasting analgesia and treats chronic pain from knee OA. In these studies, we provide the first non-Good Laboratory Practices (GLP) biosafety, efficacy, biodistribution, shedding, and histopathology examination of this rdHSV-CA8* via the intra-articular knee route of administration. Naive mice were examined for clinical safety, distribution of virus across all major tissues, knee histopathology, and analgesic efficacy. We observed no signs of persistent toxicity or histopathology, viral genomes remained where they were injected, and there was no evidence of shedding. Profound analgesia persisted for >6 months without functional impairments. These initial biosafety and efficacy data support further development of rdHSV-CA8* for treating chronic knee pain due to moderate-to-severe OA. Dr. Levitt, commented, 'Kv7 voltage-gated potassium channel activators, like rdHSV-CA8* open these channels and hyperpolarize nociceptors making them less excitable to produce profound analgesia. Kv7 activators are well-known to produce potent non-opioid-based analgesia in many human chronic pain conditions. While Kv7 openers are no longer available due to off-target adverse events related to systemic administration, they have been successfully translated from animal models to human chronic pain conditions. Bolstered by our substantial body of published data, we continue to develop our innovative approach to address the significant serious unmet need for safe and effective locally acting pain therapies to replace opioids. Our preclinical data strongly support continued preclinical development toward an IND and clinical studies of ADB-102.' The Company's lead development program for the treatment of chronic pain in knee osteoarthritis is fully funded by a UG3/UH3 grant awarded to the University of Miami by NIH/NINDS HEAL program to support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study of ADLR-1l01 in patients expected to commence in 2026. 1 Levitt et al., Biosafety and efficacy of Kv7 activating rdHSV-CA8* analgesic gene therapy for chronic pain via the intraarticular route in mice, Molecular Therapy (2025), About Carbonic Anhydrase-8 (CA8*) Gene Therapy CA8* (variants of naturally occurring human carbonic anhydrase-8 analgesic peptides) gene therapies are a novel class of neuronal calcium channel inhibitors that activate Kv7 voltage-gated potassium channels and are administered locally and long-acting. Oral small molecule pain therapeutics that activate Kv7 voltage-gated potassium channels demonstrated proven analgesic efficacy before they were removed from the market due to severe adverse events related to systemic exposure and their metabolism. CA8* gene therapy provides versatile dosing regimens and routes of administration, including intra-articular, intra-neuronal (nerve block), and intradermal injection. This non-opioid CA8* mechanism-of-action addresses neuropathic, inflammatory, and nociceptive pain, which applies to a broad range of chronic pain indications and neurological disorders. These conditions include osteoarthritis, lower back, and cancer pain; diabetes and other forms of peripheral neuropathy; as well as rare pain conditions such as erythromelalgia, a heritable chronic pain condition and epilepsy and hearing loss. About Adolore BioTherapeutics, Inc. Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for treating chronic pain using a revolutionary intra-cellular replication-defective HSV (rdHSV) drug delivery platform that is disease-free, non-toxic, and permits localized peripheral nervous system delivery of proprietary biotherapeutics. This rdHSV gene therapy technology incorporates an established re-dosing strategy and an excellent safety profile. HSV vectors are known for their stability and prolonged gene expression, providing an excellent basis for the long- term treatment of chronic pain conditions and neurological disorders. Our best-in-class CA8* programs are long-acting, locally administered gene therapies that are opioid-free Disease-Modifying Anti-Pain therapies (DMAPs) designed to treat many forms of chronic pain, epilepsy and hearing loss. Leveraging its innovative gene therapy vectors expressing CA8* analgesic peptides (ADLR-1001), Adolore is currently advancing two preclinical development programs: ADB-101 for the treatment of patients' chronic pain caused by erythromelalgia, an orphan disease, and ADB-102, their lead program for the treatment of patients with chronic pain caused by knee OA. Based on substantial compelling preclinical data generated to date, the Company is progressing these programs toward IND filings and first-in-human clinical studies. Adolore has two additional programs: ADB-104 for Drug-Resistant Refractory Focal Epilepsy and ADB-105 for Acute Severe Hearing Loss. For more information, visit Forward-Looking Statements To the extent, this announcement contains information and statements that are not historical, they are considered forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words 'believe,' 'expect,' 'anticipate,' 'intend,' 'estimate,' 'project,' 'will,' 'should,' 'may,' 'plan,' 'intend,' 'assume' and other expressions which predict or indicate future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, some of which are beyond the control of the Company. These risks and uncertainties include but are not limited to those associated with drug development. These risks, uncertainties, and other factors may cause the actual results, performance, or achievements of the Company to be materially different from the anticipated future results, performance, or achievements expressed or implied by the forward- looking statements. Investor Relations Contact Paul Barone (215)622-4542 [email protected] SOURCE: Adolore Biotherapeutics, Inc. press release
Yahoo
an hour ago
- Yahoo
Experts Say This Type Of Exercise Is The 'Fountain Of Youth'— Especially If You're Over 50
Aging gracefully isn't just about staying active; it's about choosing the right kind of activity to support your health. Resistance training (such as bodyweight, free weight, and resistance band exercises) is one of the best ways to counter the effects of aging, helping you build up muscle to support daily activities and prevent conditions like osteopenia and osteoporosis that can lead to bone fractures. And even if you've never lifted a weight before, it's never too late to start. 'Weight training is the fountain of youth,' says Abby Bales, PT, DPT, CSCS, founder of Reform Physical Therapy. 'Not only does it help increase and maintain bone density to prevent fractures, but the muscle mass that weight training builds also helps to regulate our blood sugar and metabolism.' Weight lifting can even improve balance and coordination, decreasing the frequency, severity, and likelihood of falls. On top of the physical benefits, resistance training has shown promise in staving off neurological conditions like Alzheimer's and dementia, according to a 2023 study published in Frontiers in Neuroscience, making it a multi-benefit tool for aging well. You can think of lifting weights as your body's best tool to promote resilience, energy, and independence through the aging process. Starting with small, manageable steps—such as incorporating resistance bands or light weights (at first) into your routine—can help you gain confidence and momentum while reaping the long-term benefits. Remember: Building a strength training routine doesn't have to be complicated—it just needs to be consistent. 'Start small, build gradually, and stick with it,' says Bales. She recommends starting with two or three sessions per week. Try rotating between upper body, lower body, and core exercises to keep things balanced. Progress takes time, so be patient. 'Results usually show in six to eight weeks,' Bales explains. The key is to keep showing up and enjoy the process—your future self will thank you. Need some inspiration to get started? Weight lifting later in life doesn't come without its fair share of challenges, but the rewards far outweigh the hurdles. Take it from these inspiring women, who spoke with WH previously about their later-in-life strength training journeys: Marilynn Larkin says not to let fear or self-consciousness hold you back. 'Feel your fear, then go through it,' she previously told WH. Following a cancer diagnosis, lifting weights became a way to push through her fears and embrace all that her body was capable of. '[Weight lifting] is all about allowing your body to reach its full potential and accepting it as it is.' Ginny MacColl recommends starting with a small yet challenging goal and celebrating each milestone—no matter how small, focusing on progress, not perfection. 'Little by little, these small steps lead to big changes,' she previously told WH, after becoming the oldest woman to complete an obstacle on American Ninja Warrior and breaking a Guinness World Record as a result. 'Instead of letting negativity and thoughts like 'I can't' creep in, I focus on getting stronger, physically and mentally. It works.' Michelle Alber says don't wait. After just 18 months of training focused on progressive overload (gradually increasing the weight and intensity of her workouts) and working with a coach to ensure her routine was safe and effective, she reversed her osteoporosis. 'There is never a 'perfect' time to start or a 'right' time to do anything,' she previously told WH. 'Was it hard to make major lifestyle changes at 65? Yes! But it's about choosing your 'hard' and taking control of your life.' You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals